A new trading day began on Friday, with Trevi Therapeutics Inc (NASDAQ: TRVI) stock price up 6.59% from the previous day of trading, before settling in for the closing price of $2.73. TRVI’s price has ranged from $0.97 to $4.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -67.14%. With a float of $43.76 million, this company’s outstanding shares have now reached $68.28 million.
Let’s determine the extent of company efficiency that accounts for 25 employees. In terms of profitability, gross margin is 38.64%, operating margin of -27394.89%, and the pretax margin is -25196.59%.
Trevi Therapeutics Inc (TRVI) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Trevi Therapeutics Inc is 43.08%, while institutional ownership is 41.06%. The most recent insider transaction that took place on Sep 06 ’24, was worth 12,784. In this transaction President & CEO of this company sold 4,219 shares at a rate of $3.03, taking the stock ownership to the 213,313 shares. Before that another transaction happened on Sep 09 ’24, when Company’s President & CEO sold 1,840 for $3.04, making the entire transaction worth $5,587. This insider now owns 213,313 shares in total.
Trevi Therapeutics Inc (TRVI) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.08 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -67.14% per share during the next fiscal year.
Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators
Here are Trevi Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.44, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Trevi Therapeutics Inc (TRVI)
Looking closely at Trevi Therapeutics Inc (NASDAQ: TRVI), its last 5-days average volume was 0.74 million, which is a jump from its year-to-date volume of 0.31 million. As of the previous 9 days, the stock’s Stochastic %D was 24.80%. Additionally, its Average True Range was 0.21.
During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 38.58%, which indicates a significant decrease from 45.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.18% in the past 14 days, which was higher than the 64.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.10, while its 200-day Moving Average is $2.91. However, in the short run, Trevi Therapeutics Inc’s stock first resistance to watch stands at $3.01. Second resistance stands at $3.10. The third major resistance level sits at $3.28. If the price goes on to break the first support level at $2.74, it is likely to go to the next support level at $2.56. Should the price break the second support level, the third support level stands at $2.47.
Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats
With a market capitalization of 238.43 million, the company has a total of 76,866K Shares Outstanding. Currently, annual sales are 0 K while annual income is -29,070 K. The company’s previous quarter sales were 0 K while its latest quarter income was -13,240 K.
